ORIC · Oric Pharmaceuticals, Inc.
$13.91
+0.08 (+0.58%)
At close · Aug 26
Market Cap
$1.44B
Shares
103.65M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 8-K | 2026-08-03 | — | |
| 10-Q | 2026-08-03 | 2026-06-30 | |
| 8-K | 2026-07-30 | 2026-07-28 | |
| 8-K | 2026-06-22 | 2026-06-18 | |
| Investor Event Transcript | 2026-06-09 | 2026-06-30 | |
| Investor Event Transcript | 2026-06-03 | 2026-06-30 | |
| 8-K | 2026-05-04 | — | |
| 10-Q | 2026-05-04 | 2026-03-31 | |
| DEF 14A | 2026-04-28 | 2026-06-18 | |
| 8-K | 2026-03-31 | — | |
| 10-K | 2026-02-23 | 2025-12-31 | |
| 8-K | 2026-02-23 | — | |
| 8-K | 2026-02-23 | — | |
| 8-K | 2025-12-08 | 2025-12-06 | |
| 10-Q | 2025-11-13 | 2025-09-30 | |
| 8-K | 2025-11-13 | — | |
| 8-K | 2025-11-13 | — | |
| 10-Q | 2025-08-12 | 2025-06-30 | |
| 8-K | 2025-08-12 | — | |
| 8-K | 2025-06-13 | 2025-06-11 | |
| 8-K | 2025-05-28 | 2025-05-23 | |
| 10-Q | 2025-05-05 | 2025-03-31 | |
| 8-K | 2025-05-05 | — | |
| DEF 14A | 2025-04-23 | 2025-06-11 | |
| 8-K | 2025-03-14 | 2025-03-11 | |
| 8-K | 2025-02-25 | — | |
| 10-K | 2025-02-18 | 2024-12-31 | |
| 8-K | 2025-02-18 | — | |
| 8-K | 2025-01-13 | — | |
| 10-Q | 2024-11-12 | 2024-09-30 | |
| 8-K | 2024-11-12 | — | |
| 10-Q | 2024-08-12 | 2024-06-30 | |
| 8-K | 2024-08-12 | — | |
| 8-K | 2024-06-14 | 2024-06-12 | |
| 8-K | 2024-05-06 | — | |
| 10-Q | 2024-05-06 | 2024-03-31 | |
| DEF 14A | 2024-04-24 | 2024-06-12 | |
| 8-K | 2024-03-29 | 2024-03-26 | |
| 10-K | 2024-03-11 | 2023-12-31 | |
| 8-K | 2024-03-11 | — | |
| 8-K | 2024-01-22 | 2024-01-20 | |
| 8-K | 2024-01-09 | — | |
| 8-K | 2023-12-11 | — | |
| 10-Q | 2023-11-06 | 2023-09-30 | |
| 8-K | 2023-11-06 | — | |
| 8-K | 2023-10-23 | 2023-10-21 | |
| 10-Q | 2023-08-10 | 2023-06-30 | |
| 8-K | 2023-08-10 | — | |
| 8-K | 2023-06-27 | 2023-06-24 | |
| 8-K | 2023-06-15 | 2023-06-14 |
Showing 1–50 of 98 filings
Key facts
CIK
1796280
CUSIP
68622P109
13F (30d)
165 filings
165 filers
Visit website
Investor relations